{"name":"Archigen Biotech Limited","slug":"archigen-biotech-limited","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"SAIT101","genericName":"SAIT101","slug":"sait101","indication":"Relapsing forms of multiple sclerosis","status":"phase_3"}]}],"pipeline":[{"name":"SAIT101","genericName":"SAIT101","slug":"sait101","phase":"phase_3","mechanism":"SAIT101 is a small molecule that targets the S1P1 receptor.","indications":["Relapsing forms of multiple sclerosis"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiakFVX3lxTE5RckxOb1lQbWJoU0JxRFRHT0JsOUwtNDBySFYzeUZMNEpWM1EyaWxRMW1zLTJxZlczSU5FRzBGajVGbTUzTlFjZExoNVlUQVFQMDdtbGtnWXZjLXRkNGZreEFpelh3dkE0OEE?oc=5","date":"2022-10-04","type":"patent","source":"Wiley Online Library","summary":"Oncology biosimilars: New developments and future directions - Bachu - 2022 - Cancer Reports - Wiley Online Library","headline":"Oncology biosimilars: New developments and future directions - Bachu - 2022 - Cancer Reports","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiVkFVX3lxTFBWcmNBQnJGUnd1U1JDaXppeDh0SHNoeWpvS3hwV0hCWEE2THJ3NVZCMHQ1ajVwMUM0T1RCdFA0QWVsU0ZiYXZsTFBWN2ozY051RlY2MUhn?oc=5","date":"2022-05-24","type":"pipeline","source":"The Korea Herald","summary":"Samsung Biologics, AstraZeneca shutting down their joint venture Archigen Biotech - The Korea Herald","headline":"Samsung Biologics, AstraZeneca shutting down their joint venture Archigen Biotech","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}